Intravoxel Incoherent Motion (IVIM) Magnetic Resonance Imaging in Multiple Sclerosis
What it found
No result yet.
What was tested
Treatment tested
- Diffusion-weighted magnetic resonance imaging
What it measured
Main measures
IVIM parameters (including ADC,D,D*,f) in Multiple Sclerosis brain regions.
Up to 2 months
MRI lesions
Who could take part
Relapsing MS · 18 and over
Inclusion Criteria: 1. Patients who are 18 years or older. 2. Relapsing-remitting MS diagnosed as per Macdonald criteria Exclusion Criteria: 1. Contraindication to MRI. For example, metal implantation in the body, claustrophobia and pregnancy. 2. Patients who are unable to tolerate the scans without moving the head as a result of symptoms such as tremor, spasticity, involuntary movements and spasms, cognitive impairment, coughing, and shortness of breath.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Intravoxel incoherent motion (IVIM) is technique based on diffusion-weighted imaging (DWI). In this study, the investigators evaluate the use of IVIM in patients with Multiple Sclerosis.
Loading reviews and guidelines…
Related trials
- INFLANET
Not a drug-phase study · Recruiting
Still running
- FREXALT
Phase 3 · Running, not recruiting
Still running
- REMYELIKIDS
Not a drug-phase study · Recruiting
Still running
- Effect of Alemtuzumab on Microglial Activation Positron E…
Phase 1 / Phase 2 · Withdrawn
Stopped early
- 9-month Study to Assess the Efficacy of Ofatumumab on Mic…
Phase 3 · Completed
Results posted, no main test reported
- MS_SV2
Phase 2 · Completed
No result found
History
Started
Jan 2023
Main results due
Dec 2026
Finished
Dec 2026
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error